Safety: what progress in understanding and addressing immune-related adverse events?

IMMUNO-ONCOLOGY INSIGHTS

Safety: what progress in understanding and addressing immune-related adverse events?

June 2022
Safety: what progress in understanding and addressing immune-related adverse events?
Download PDF

Foreword

Putting the patient first

Putting the patient first

Róisin McGuigan
11 June 2022
Read

Commentary

Addressing the challenges of CRS in bispecific monoclonal antibody cancer therapy

Addressing the challenges of CRS in bispecific monoclonal antibody cancer therapy

Anjali Vaze, Peter Kuebler
16 June 2022
Read
Patient-centered care in immuno-oncology: current progress & opportunities when considering safety & tolerability

Patient-centered care in immuno-oncology: current progress & opportunities when considering safety & tolerability

Céline Adessi, Dominik Rüttinger
18 May 2022
Read

Viewpoint

Redefining success: predicting checkpoint inhibitor toxicity to improve patient outcomes

Redefining success: predicting checkpoint inhibitor toxicity to improve patient outcomes

Joanne Weidhaas
13 June 2022
Read
Understanding the evolving safety landscape in autologous and allogeneic CAR-T therapy

Understanding the evolving safety landscape in autologous and allogeneic CAR-T therapy

Elaine Murray McCracken
6 June 2022
Read